Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.

PloS one - 1 Jan 2014

Li Yingbo, Wang Jinxi, Gao Xing, Han Weihua, Zheng Yongxiang, Xu Huan, Zhang Chuanling, He Qiuchen, Zhang Lihe, Li Zhongxin, Zhou Demin

Abstract excerpt

Although EGFR-targeted therapy has been beneficial to colorectal cancer patients, several studies have showed this clinical benefit was restricted to patients with wild-type KRAS exon 2 colorectal cancer. Therefore, it is crucial to explore efficient treatment strategies in patients with KRAS mutations. c-Met is an emerging target for the development of therapeutics against colorectal cancer. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gamma Rays

Share to HCT116 Cells

Share to Mice, Nude

Share to Proto-Oncogene Proteins c-met

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25427200
DOI: 10.1371/journal.pone.0113186
PMCID: PMC4245100

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.PMID 25427200Read ↗

Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.Semantic proximity Read ↗

KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.Semantic proximity Read ↗

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.Semantic proximity Read ↗

Targeting c‐MET by LY2801653 for treatment of cholangiocarcinomaSemantic proximity Read ↗

Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer.Semantic proximity Read ↗

Combination effect of cetuximab with radiation in colorectal cancer cells.Semantic proximity Read ↗

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.Semantic proximity Read ↗

Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy.Semantic proximity Read ↗

Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine RestrictionSemantic proximity Read ↗

A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.Semantic proximity Read ↗

Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line.Semantic proximity Read ↗

Increased response to immune checkpoint inhibitors with dietary methionine restrictionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.